logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-3. HIV prevalence among injecting drug users – studies with national and subnational coverage [see all figures in this series...]

Part (ii) Young injecting drug users (aged under 25), 2004 - 2005


Red square = samples with national coverage; green triangle = samples with subnational (including local or regional) coverage.

Differences between countries should be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary and some sample sizes are small.

Data for Czech Republic and Portugal include non-IDUs and therefore may underestimate prevalence among IDUs (estimated proportion of non-IDUs in the samples not known).

Data for Czech Republic, Spain, Luxembourg and Slovakia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. In addition, data may not be representative for people who are in treatment - this is known to be the case for Belgium.

Data for Czech Republic, France and Luxembourg are based on self-reported test results, which are less reliable than clinically- documented tests.

Data for France and Latvia are from 2003 (see sources).

Data for Sweden concern 2006.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.


SB2006: Figure INF-3 part (ii)

For primary sources, study details and data before 2004, see Table INF-9 part (i), Table INF-9 part (ii) and Table INF-0.

See also 'General notes for interpreting data' on the Explanatory notes and help page.


Reitox national focal points

Page last updated: Friday, 23 November 2007